Why is Caribou Biosciences Stock (CRBU) Down 43% Today?
Shares in Caribou Biosciences ($CRBU) plunged over 43% today as investors reacted to the company’s decision to potentially put itself up for sale a...
Cabaletta Bio Inc. (CABA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 9,174,758 | $28,533,497 | +4% | 0.04% |
| 2. | Cormorant Asset Management Bihua Chen | 5,000,000 | $15,550,000 | -10% | 0.8% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,200,142 | $13,062,442 | +236% | 0.04% |
| 4. | Opaleye Management James A. Silverman | 3,863,800 | $12,016,418 | +180% | 1.09% |
| 5. | Citadel Investment Group Ken Griffin | 3,522,112 | $10,953,768 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.26 | 8,800 | $19,888.00 | 8,800 | 2026-01-21 | Filing | |
| $2.19 | 11,312 | $24,763.10 | 31,312 | 2026-01-21 | Filing | |
| $2.21 | 22,725 | $50,322.24 | 22,725 | 2026-01-21 | Filing | |
| $2.27 | 22,170 | $50,215.05 | 22,170 | 2026-01-21 | Filing | |
| $2.27 | 4,405 | $9,982.17 | 5,405 | 2026-01-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.33 | 700 | $14,228.62 | 20,000 | 2024-01-19 | Filing | |
| $19.54 | 10,300 | $201,210.50 | 20,700 | 2024-01-19 | Filing | |
| $22.22 | 3,132 | $69,593.35 | 20,000 | 2023-12-19 | Filing | |
| $21.76 | 7,868 | $171,195.88 | 23,132 | 2023-12-19 | Filing | |
| $18.02 | 7,458 | $134,405.09 | 20,000 | 2023-11-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 556,235 | $1,067,971 | 0.02% | |
| 2. | 400,000 | $792,000 | 0.01% | |
| 3. | 75,960 | $145,843 | 0% | |
| 4. | 33,061 | $63,477 | 0% | |
| 5. | 30,935 | $61,251 | 0% |
News See All
10 Small Cap Stocks with Potential to Rise 1000 Percent
In this article, we look at 10 Small Cap Stocks with Potential to Rise 1000 Percent. Small-cap stocks have returned to the market’s risk conversation in 2026.
Investors' Stock Portfolio: Top 10 Penny Stocks To Buy
In this article, we will discuss Investors' Stock Portfolio: Top 10 Penny Stocks To Buy. Risk appetite, driven by artificial intelligence fervor, continues to drive sentiment in US equity markets.
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here.
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials
Cabaletta Bio Inc. (NASDAQ:CABA) is one of the best stocks under $3 to invest in.
10 Best Stocks Under $3 to Invest In
On October 16, Victoria Greene, Chief Investment Officer of G Squared Private Wealth Management, appeared on CNBC to state that small caps demonstrate lasting strength.
Several Headwinds Dragged Cabaletta Bio (CABA) in Q2
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S.
10 Most Shorted Stocks That Are Loved by Analysts
In this piece, we will take a look at the 10 most shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making money on the stock market.
Jim Cramer’s 10 Latest Stock Picks This Week
In this article, we will take a detailed look at Jim Cramer’s 10 Latest Stock Picks This Week. For a quick overview of such stocks, read our article Jim Cramer’s 5 Latest Stock Picks This Week.
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Hedge Fund Resource Center